Main image Main image

Cend Therapeutics in the News

January 26, 2018

An independent group has published findings how a simple
iRGD / CEND-1 coadministration method can improve the entry of tumor-targeting immune cells into tumors. There are several potential therapeutic options for the method that could enhance the clinical efficacies of available cancer immunotherapies.

Tumor-penetrating peptide iRGD conjugation effectively potentiates intratumor T cell infiltration

January 1, 2018

Click here for more information.

November 26, 2017

DrugCendR will present at the Biotech Showcase and schedule one-to-one meetings during the conference. Investors who wish to meet with Harri Jarvelainen for a one-to-one meeting should send direct inquiry to the company.